HIV drug nevirapine (Viramune): risk of severe hepatotoxicity

被引：6
|
作者：
Wooltorton, E
机构：
来源：
CANADIAN MEDICAL ASSOCIATION JOURNAL | 2004年 / 170卷 / 07期
关键词：
D O I：
10.1503/cmaj.1040417
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1091 / 1091
页数：1
相关论文
共 50 条
  • [21] Malaria therapy in HIV: drug interactions between nevirapine and quinine
    Uriel, A.
    Lewthwaite, P.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2011, 22 (12) : 768 - 768
  • [22] Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya
    Angira, F.
    Peters, P. J.
    Polle, N.
    Zeh, C.
    Masaba, R.
    Borkowf, C. B.
    Oyaro, B.
    Omolo, P.
    Ogindo, P.
    Ndivo, R.
    Lando, R.
    Fowler, M. G.
    Weidle, P. J.
    Thomas, T. K.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59
  • [23] Nevirapine-associated hepatotoxicity and rash among HIV-infected pregnant women in Kenya
    Angira, F.
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2012, 17 : 5 - 5
  • [24] Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    Martínez, E
    Blanco, JL
    Arnaiz, JA
    Pérez-Cuevas, JB
    Mocroft, A
    Cruceta, A
    Marcos, MA
    Milinkovic, A
    García-Viejo, MA
    Mallolas, J
    Carné, X
    Phillips, A
    Gatell, JM
    AIDS, 2001, 15 (10) : 1261 - 1268
  • [25] Comparison of 48 week efficacy, pharmacokinetics and safety of 400 mg QD nevirapine (NVP) extended release (Viramune XR) versus 200 mg BID nevirapine immediate release (Viramune IR) formulations in combination with emtricitabine/tenofovir in antiretroviral (ARV) naive HIV-1 infected patients (VERxVE)
    Gathe, J. C.
    Bogner, J. R.
    Santiago, S.
    Horban, A.
    Nelson, M.
    Cahn, P.
    Andrade, J.
    Spencer, D.
    Yong, C.
    Nguyen, T.
    Zhang, W.
    Drulak, M.
    Quinson, A.
    ANTIVIRAL THERAPY, 2010, 15 (08) : A71 - A72
  • [26] The plasma pharmacokinetics of nevirapine (Viramune®) in a once daily (QD) and twice daily (BID) regimen.
    van Heeswijk, RPG
    Veldkamp, AI
    Wit, FWNM
    Hoetelmans, RMW
    Meenhorst, PL
    Mulder, JW
    Lange, JMA
    Reiss, P
    Beijnen, JH
    AIDS, 1998, 12 : S32 - S32
  • [27] Risk of severe hepatotoxicity/liver injury with eltrombopag
    Reactions Weekly, 2016, 1618 (1) : 5 - 5
  • [28] Nevirapine and liver hepatotoxicity:: relevance in clinical practice
    Font, C
    Guitart, R
    Sóler, A
    Vila, M
    Mas, P
    Villà, C
    Pedrol, E
    AIDS, 2000, 14 : S63 - S63
  • [29] Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan
    Tseng, Yu-Tzu
    Yang, Chia-Jui
    Chang, Sui-Yuan
    Lin, Shu-Wen
    Tsai, Mao-Song
    Liu, Wen-Chun
    Wu, Pei-Ying
    Su, Yi-Ching
    Luo, Yu-Zhen
    Yang, Shang-Ping
    Hung, Chien-Ching
    Chang, Shan-Chwen
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2014, 29 : 12 - 17
  • [30] 2′-Deoxythymidine Adducts from the Anti-HIV Drug Nevirapine
    Antunes, Alexandra M. M.
    Wolf, Benjamin
    Conceicao Oliveira, M.
    Beland, Frederick A.
    Matilde Marques, M.
    MOLECULES, 2013, 18 (05) : 4955 - 4971
12345